Telomir Pharmaceuticals, Inc. (TELO) stock
TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.36−0.08 (-17.24%)
Close on Nov 20, 2026Market cap $25.03MP/E –Yield –
Telomir Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
Telomir Pharmaceuticals's net income for the twelve months ending Sep 30, 2026 was -$5.48M. For fiscal 2025 it was -$10.41M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.41M | – |
| FY2024 | Dec 31, 2024 | -$16.53M | – |
| FY2023 | Dec 31, 2023 | -$13.07M | – |
| FY2022 | Dec 31, 2022 | -$854.15K | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$705.23K | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.72M | – |
| Q1 FY2026 | Mar 31, 2026 | -$990.95K | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.10M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.90M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.55M | – |
| Q1 FY2023 | Mar 31, 2023 | -$482.94K | – |
See a number that looks wrong?